Moxibustion therapy in Chinese patients with ankylosing spondylitis: A randomized controlled pilot trial

Wang, Hongyuan; Xu, Xiao; Li, Li; Ding, Cai-Yan; Lü, Jiafeng; Zhang, Yongyi; Zhang, Yufei; Zhang, Yanling; Sun, Zhi-Qin

doi:10.1016/j.eujim.2019.100952

Cited by 5 publications

(6 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On an individual basis, physiotherapy should be considered, especially if a patient does not exercise on their own. The task force underlined that physiotherapy should not be an umbrella term also used for interventions that are not widely tested or have proven benefit, like needle knife or complementary medicine-derived practices 14 59 60. After discussion, the task force concluded that ‘physiotherapy’ is a more appropriate term than ‘physical therapy’ as used in the previous version of the recommendations and therefore this small change was incorporated.…”

Section: Resultsmentioning

confidence: 99%

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

et al. 2022

View full text Add to dashboard Cite

ObjectivesTo update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for the management of axial spondyloarthritis (axSpA).MethodsFollowing the EULAR Standardised Operating Procedures, two systematic literature reviews were conducted on non-pharmacological and pharmacological treatment of axSpA. In a task force meeting, the evidence was presented, discussed, and overarching principles and recommendations were updated, followed by voting.ResultsFive overarching principles and 15 recommendations with a focus on personalised medicine were agreed: eight remained unchanged from the previous recommendations; three with minor edits on nomenclature; two with relevant updates (#9, 12); two newly formulated (#10, 11). The first five recommendations focus on treatment target and monitoring, non-pharmacological management and non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice pharmacological treatment. Recommendations 6–8 deal with analgesics and discourage long-term glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for pure axial involvement. Recommendation 9 describes the indication of biological DMARDs (bDMARDs, that is, tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i)) and targeted synthetic DMARDs (tsDMARDs, ie, Janus kinase inhibitors) for patients who have Ankylosing Spondylitis Disease Activity Score ≥2.1 and failed ≥2 NSAIDs and also have either elevated C reactive protein, MRI inflammation of sacroiliac joints or radiographic sacroiliitis. Current practice is to start a TNFi or IL-17i. Recommendation 10 addresses extramusculoskeletal manifestations with TNF monoclonal antibodies preferred for recurrent uveitis or inflammatory bowel disease, and IL-17i for significant psoriasis. Treatment failure should prompt re-evaluation of the diagnosis and consideration of the presence of comorbidities (#11). If active axSpA is confirmed, switching to another b/tsDMARD is recommended (#12). Tapering, rather than immediate discontinuation of a bDMARD, can be considered in patients in sustained remission (#13). The last recommendations (#14, 15) deal with surgery and spinal fractures.ConclusionsThe 2022 ASAS-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.

show abstract

Section: Resultsmentioning

confidence: 99%

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These identifying acupuncture points were based on TCM theory and found effective in ameliorating symptoms of AS in our previous clinical trial. 7 Prior to moxibustion stimulation, mice in the MA group were fixed in a prone position on a board after shaving the hair to expose the skin and sterilizing the skin surface at GV4, bilateral BL23 and bilateral ST36 acupuncture points. As previously described 11 , the moxa cone was lit for about 5 seconds and then placed on choosing acupuncture points with the fire head 2 cm from the skin surface.…”

Section: Methodsmentioning

confidence: 99%

“…Several clinical trials and systematic reviews suggested that moxibustion as an adjuvant therapy in combination with NSAIDs or biological agents may exert positive effects on AS patients. 6 , 7 , 8 Potential mechanisms have been suggested that inhibition of non-specific endochondral ossification of spine 9 , regulating immune function 10 , anti-inflammation, anti-oxidant, anti-muscle degenerative and cartilage-protective effect. 11 …”

Section: Introductionmentioning

confidence: 99%

Metabolomic analysis of biochemical changes in the tissue and urine of proteoglycan-induced spondylitis in mice after treatment with moxibustion

Shi

Wang

et al. 2021

Integrative Medicine Research

Self Cite

View full text Add to dashboard Cite

Background Moxibustion is widely used in East Asian countries to manage the symptom of rheumatic diseases. The aim of this study was to identify potential metabolic profiles of moxibustion on relieving ankylosing spondylitis (AS) mice through UHPLC-Q-TOF/MS metabolomic study. Methods Thirty-two female Balb/c mice were randomized into healthy control (HC), AS model, moxibustion at acupuncture points (MA) in AS model, and moxibustion at non-acupuncture points (MNA) AS model groups. Moxibustion was administered daily at GV4, bilateral BL23 and bilateral ST36 acupuncture points for four weeks in the MA group. The overall health status, the thickness of hind paws and the tissue concentrations of IL-1β, PGE 2 , IL-6 and TNF-α were assessed. The UHPLC-Q-TOF/MS was used to explore the perturbations of endogenous metabolites in tissue and urine of AS model mice intervened by moxibustion. Results Compared with the AS group, the overall health status was significantly improved after 4-week moxibustion intervention ( p < 0.05) . The results also showed that MA significantly reduced the levels of paw thickness and decreased the levels of four cytokines in the tissue ( p < 0.01). Thirty-seven endogenous metabolites identified by the OPLS-DA were considered to be contributing to therapeutic effects of moxibustion. Moreover, metabolic pathway analysis further revealed that the identified metabolites were mainly involved in TCA cycle, Lipid metabolism, Amino Acid metabolism, Intestinal flora metabolism and Purine metabolism. Conclusions UHPLC-Q-TOF/MS based metabolomics approach, as a novel and powerful tool, can help us to gain the insights into potential mechanisms of action of moxibustion for AS.

show abstract

“…Therefore, moxibustion can reduce inflammation, repair gastrointestinal mucosa, and decrease gastrointestinal hypomotility, which can alleviate the side effects of surgery and radiotherapy. It has been used for the treatment of acute abdominal pain, vomiting, diarrhea, and dysentery [28].…”

Section: Discussionmentioning

confidence: 99%

Observation of the effects of moxibustion on acute and chronic radiation enteritis in cervical patients

Wu¹,

Xiao²,

Gong³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundThe present prospective, observational study evaluated the safety and efficacy of moxibustion in preventing acute and chronic radiation enteritis post-radiation in patients with cervical cancer.MethodsBetween March 2015 and October 2018, 90 patients with stage I-IV cervical cancer were treated with radiation at the Guangzhou University of Chinese Medicine Second Affiliated Hospital (Guangdong Provincial Hospital of Chinese Medicine). The patients were randomly divided into a moxibustion group and a control group. The moxibustion group received moxibustion on Guānyuán (RN4), Qìhǎi (RN6), Shénquē (RN8) and Tiānshū (ST25) during radiation. The control group received radiotherapy only. We observed and compared the occurrence of acute radiation enteritis (ARE) between the two groups of patients during radiotherapy. Then, the patients were followed-up 1-1.5-year after radiation, and we observed and compared the occurrence of chronic radiation enteritis (CRE) between the two groups.ResultsThe incidence of ARE was significantly lower in the moxibustion group (10.9%) than the control group (36.4%; P < 0.05). At follow-up post-radiotherapy, the incidence of CRE was significantly reduced (15.2%) in the moxibustion group compared with the control group (35.7%; P < 0.05).ConclusionsMoxibustion significantly improved physical function and reduce the gastrointestinal response caused by radiotherapy, thus the occurrence of acute and chronic radiation enteritis was reduced. These results can improve the therapeutic effect of radiation and improve the patient’s quality of life.Trial registrationProspective clinical trial for the effects of moxibustion on acute and chronic radiation enteritis in cervical patients. ChiCTR2000029650. Registered: February 9, 2020-Retrospectively registered.

show abstract

Moxibustion therapy in Chinese patients with ankylosing spondylitis: A randomized controlled pilot trial

Cited by 5 publications

References 71 publications

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Metabolomic analysis of biochemical changes in the tissue and urine of proteoglycan-induced spondylitis in mice after treatment with moxibustion

Observation of the effects of moxibustion on acute and chronic radiation enteritis in cervical patients

Contact Info

Product

Resources

About